

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSE ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.



(Please scan the QR to view the Prospectus)



PHYTOCHEM REMEDIES (INDIA) LIMITED

Corporate Identity Number: U17014RJ2002PLC017943

Our Company was originally incorporated and registered as a private limited Company under Companies Act, 1956 under the name and style of "Phytochem Remedies (India) Private Limited" vide Certificate of Incorporation dated November 27, 2002 bearing registration number 017943 and bearing Corporate Identity Number U24233RJ2002PTC017943, issued by the Registrar of Companies. Further, pursuant to a resolution passed by our Board at a board meeting held on April 07, 2025 and a special resolution passed by our shareholders at an extra-ordinary general meeting held on April 10, 2025, our Company was converted into a public limited company. Consequently, the name of our Company was changed to "Phytochem Remedies (India) Limited" and a fresh Certificate of Incorporation dated April 23, 2025 bearing Corporate Identity Number U17014RJ2002PLC017943 was issued by Registrar of Companies, Central Processing Centre. For details of change in name and registered office of our Company, please refer to chapter titled "History and Certain Corporate Matters" beginning on page 189 of the Prospectus.

Registered Office: 220, Ashok Nagar Main Road, Udaipur City, Udaipur, Girwa, Rajasthan, India, 313001.

Tel: +91 294 4577549; Contact Person: Namrata Paliwal, Company Secretary and Compliance Officer

E-mail: cs@phytochem.co.in; Website: www.phytochem.co.in; Corporate Identity Number: U17014RJ2002PLC017943

PROMOTERS OF OUR COMPANY ARE ADITI BOHRA, BOHRA AGRIFILMS PRIVATE LIMITED, NIRANJAN SURANA AND SHILPA SURANA

THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED (BSE SME).

THE ISSUE

INITIAL PUBLIC OFFER OF 39,00,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF PHYTOCHEM REMEDIES (INDIA) LIMITED (OUR "COMPANY") FOR CASH AT AN ISSUE PRICE OF ₹ 98.00/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 88.00/- PER EQUITY SHARE), AGGREGATING ₹ 3,822.00 LAKHS ("PUBLIC OFFER") OUT OF WHICH 1,96,800 EQUITY SHARES AGGREGATING TO ₹ 192.86 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE ("MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 37,03,200 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹ 98.00/- PER EQUITY SHARE FOR CASH, AGGREGATING ₹ 3,629.14 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 33.12 % AND 31.45 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" ON PAGE 323 OF THE PROSPECTUS.

PRICE: ₹ 98 PER EQUITY SHARE OF FACE VALUE OF 10/- EACH

THE ISSUE PRICE IS 9.8 TIMES THE FACE VALUE OF THE EQUITY SHARES

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2024-25 IS 17.25

BIDS CAN BE MADE FOR A MINIMUM OF 2400 EQUITY SHARES AND IN MULTIPLES OF 1200 EQUITY SHARES THEREAFTER.

BID/ISSUE PROGRAMME

ISSUE OPENS ON : THURSDAY, DECEMBER 18, 2025

ISSUE CLOSES ON : MONDAY, DECEMBER 22, 2025



Simple, Safe, Smart way of making an application - Make use of it

*Application supported by block amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, for further details check section on ASBA below.

Mandatory in public issue. No cheques will be accepted.



UPI – Now available in ASBA for Retail Individual Investors and Non - Institutional Investor applying for amount upto ₹ 5,00,000/-, applying through Registered Brokers, DPs and RTAs. UPI Bidder also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020, issued by the Central Board of Direct Taxes and the subsequent press releases, including press releases dated June 25, 2021 and September 17, 2021 and CBDT circular no.7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

BRIEF DESCRIPTION OF THE BUSINESS OF THE ISSUER

Our Company is one of the leading manufacturers of high-quality corrugated boxes including printed, rolls, pads, sheets etc., offering customized packaging solutions to meet the specific requirements of its clients. Our company specialises in manufacturing corrugated boxes and supplies to various sectors (Source: D&B Report). Incorporated in 2002, the company initially focused on development and planning, with manufacturing operations commencing in 2014. Since then, our company has grown significantly and leveraging its state-of-the-art manufacturing facilities.

Our company operates from its strategically located manufacturing units in Bari Brahmana, Jammu, which provide significant logistical advantages. Over the year, Company has expanded its reach and built a strong regional presence in Jammu, India while also establishing a marketing and distribution network across multiple states (Source: D&B Report).

With a strong focus on innovation and customer satisfaction, we have built a reputation for delivering durable and cost effective packaging solutions. We operate in two units at Bari Brahmana, Jammu, with Unit 1 having a total allocated area of 43,360 Sq. Ft. and Unit 2 having an allocated area of 1,73,440 Sq. Ft. Currently, Unit 1 is utilizing approximately 12,000 Sq. Ft. and Unit 2 is utilizing approximately 55,000 Sq. Ft. of total area of respective units. Out of the total land area, approximately 15,000 Sq. Ft. in Unit 1 and around 75,000 Sq. Ft. in Unit 2 remain unutilized and shall be used for the construction and installation of new manufacturing machineries to accommodate both present and future expansion.

Our manufacturing journey started with a Semi-Automatic Manufacturing Line in 2014. Even with Market standards of 2014, this line had all latest machines and other facilities to give quick service to the customers, which continues to contribute to revenue and profitability. To further strengthen our production capabilities, we established a fully automatic corrugated board plant in 2022 in an extensive area of 75,000 sq. ft. equipped with the latest technology. This facility enables our company to cater to a broader range of packaging needs of our customer with improved efficiency and precision.

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF BSE.

FOR THE PURPOSE OF THE ISSUE THE DESIGNATED STOCK EXCHANGE SHALL BE BSE.

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE PROSPECTUS AND THE TERMS OF THE ISSUE.

INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE ISSUE AVAILABLE IN ANY MANNER.

RISK IN RELATION TO THE ISSUE

- We derive 51.62 % of our revenue from our top ten customers, 41.01% of our revenue is derived from our top five customers and further, our top three customers collectively accounted for approximately 31.18% of our revenue for six months ended September 30, 2025. Loss of such customers or reduction in business from such customers, the deterioration of their financial condition or prospects, or a reduction in their demand for our products could adversely affect our business, results of operations, financial condition and cash flows.
- We do not have continuing or exclusive arrangements with any of our suppliers of materials and other material inputs. Loss of suppliers or any failure by our suppliers to make timely delivery of materials may have an adverse effect on our business, supply chain, results of operations, financial condition and cash flows.
- Our business is dependent and will continue to depend on our manufacturing facilities situated in Jammu, India which exposes us to regional risks and risks in relation to our manufacturing process. Any disruption, slowdown, or shutdown in our manufacturing operations or other manufacturing, or production problems caused by unforeseen events could adversely affect our business, results of operations, financial condition and cash flows.
- We are significantly dependent on our customers located in a single geographical region i.e. Jammu and Kashmir. Loss of customers and revenue in Jammu, India could materially affect our business, results of operations, and financial condition.
- We may not be able to collect receivables due from our customers, in a timely manner, or at all, which may adversely affect our business, financial condition, results of operations and cash flows. As of September 30, 2025, Fiscal 2024 and Fiscal 2023, our trade receivables were ₹1,247.94 lakhs, ₹942.69 lakhs, ₹659.65 lakhs and ₹532.33 lakhs respectively
- Some of the immediate relatives of our Promoters, who are deemed to be a part of the Promoter Group under SEBI ICDR Regulations have not provided consent, information or any confirmations or undertakings pertaining to themselves which are required to be disclosed in relation to a member of the Promoter Group.

1. Weighted Average Return on Net worth (RoNW)

As per the Restated Financial Statements:

Financial Year ended	RoNW (%)	Weight
March 31, 2025	34.07	3
March 31, 2024	26.46	2
March 31, 2023	12.75	1
Weighted Average		27.98
September 30, 2025*		22.22

*Not annualised
Notes:

i. Weighted average = Aggregate of financial year-wise weighted Net Worth divided by the aggregate of weights i.e. (Net Worth x Weight) for each financial year / Total of weights

ii. Return on Net Worth (%) = Net profit after tax, as restated / Net worth as restated as at period/year end.
Net worth means the aggregate value of the paid up share capital of the Company and all reserves created out of profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, capital reserve, foreign currency translation reserve, write-back of depreciation as at period /year end, as per Restated Financial Statement of Assets and Liabilities of the Company.

2. Past Primary/ Secondary Transactions

There have been no primary or secondary sale/ acquisitions of Equity Shares or any convertible securities, where the Promoters, members of the promoter group, Selling Shareholders, or shareholder(s) having the right to nominate director(s) in the board of directors of the Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this certificate, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days except as follows:

Weighted Average Cost of Acquisition ("WACA") and Issue price

Sr. no.	Name of The Shareholder	Nature of transactions	No. of Shares (Actual)	Issue price (in ₹)	Total consideration (in ₹)
1	Niranjan Surana	Right Issue	3,00,000	10	30,00,000
2	Niranjan Surana	Bonus Issue	17,40,000	Nil	Nil
3	Bohra Agrifilm Private Limited	Bonus Issue	20,71,050	Nil	Nil
4	Aditi Bohra	Bonus Issue	7,63,905	Nil	Nil
5	Shilpa Surana	Bonus Issue	1,50,000	Nil	Nil
6	Niranjan Surana	Transfer	2,18,500	10	21,85,000

Type of transaction	WACA (in ₹)	Issue Price (in ₹)
Weighted average cost of acquisition of primary issuances	0.60	98
Weighted average cost of acquisition of secondary issuances	10.00	98

Contd.

ADDITIONAL INFORMATION FOR INVESTORS

- Details of proposed/undertaken pre-issue placements from the Prospectus filing date:**
None
- Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the Prospectus filing date:**
Our promoter(s) and promoter group(s) have not undertaken any transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company from the Prospectus filing date.
- Pre-Issue Shareholding as at the date of advertisement and post-issue shareholding as at allotment for Promoter(s)/Promoter Group and additional top 10 Shareholders of the Company is as under:**

Sr No.	Name of the Shareholder (I)	Pre-Issue		Post Issue	
		No. of Equity Shares (II)	% of pre-Issue capital (IV)	No. of Equity Shares (V)	% of post-Issue capital (VI)
A)	Promoter				
1	Niranjan Surana	29,00,000	36.83 %	29,00,000	24.63%
2	Shilpa Surana	2,50,000	3.17 %	2,50,000	2.12%
3	Aditi Bohra	12,73,175	16.17 %	12,73,175	10.81%
4	Bohra Agrifilms Private Limited	34,51,750	43.83 %	34,51,750	29.31%
	Sub Total (A)	78,74,925	100.00%	78,74,925	66.88%
B)	Promoter Group				
	Sub Total (B)				
	Total (A+B)	78,74,925	100.00%	78,74,925	66.88%

As of the date of the Prospectus, our promoter group does not hold any shares in the Company.

Note: There is no Offer for Sale from the existing shareholders of the Company in the present issue of the Issuer For further details, see the chapter titled "Capital Structure" beginning on page 82 of the Prospectus.

BASIS FOR THE ISSUE PRICE

The Issue Price has been determined by our Company, in consultation with the Lead Manager, on the basis of key business strategy and assessment of market demand for the Equity Shares offered through the Fixed Price and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹ 10 each and the Issue Price is 9.8 times the face value. Investors should read the following basis with the section titled "Risk Factors" and chapters titled "Restated Financial Information", "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Our Business" beginning on page 29, 220, 266 and 158 respectively, of the Prospectus to get a more informed view before making any investment decisions.

AN INDICATIVE TIMELINE FOR THE ISSUE:

Bid/Issue Period (except the Bid/Issue Closing Date)	
Submission and Revision in Bids	Only between 10.00 a.m. and 5.00 p.m. Indian Standard Time ("IST")
Bid/Issue Closing Date*	
Submission of Electronic Applications (Online ASBA through 3-in-1 accounts) - For Individual Investors	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA applications where Bid Amount is up to ₹ 5,00,000)	Only between 10.00 a.m. and up to 4.00 p.m. IST
Submission of Electronic Applications (Syndicate Non Individual Investors, Non-Individual Applications)	Only between 10.00 a.m. and up to 3.00 p.m. IST
Submission of Physical Applications (Bank ASBA)	Only between 10.00 a.m. and up to 1.00 p.m. IST
Submission of Physical Applications (Syndicate Non Individual Investors, Non-Individual Applications of QIBs and NII where Bid Amount is more than ₹500,000)	Only between 10.00 a.m. and up to 12.00 p.m. IST
Modification/Revision/cancellation of Bids	
Upward Revision of Bids by Individual Investors and Non Individual Investors categories ^B	Only between 10.00 a.m. and up to 4.00 p.m. IST on Bid/ Issue Closing Date

*UPI mandate and time and date shall be at 5:00 p.m. on Issue Closing Date

^BOther Investors can neither revise their bids downwards nor cancel / withdraw their applications.

ISSUE PROGRAM

An indicative timetable in respect of the issue is set out below:

EVENTS	INDICATIVE DATES
Bid/Issue Opening Date	December 18, 2025
Bid/Issue Closing Date	December 22, 2025
Finalization of Basis of Allotment with the Designated Stock Exchange	On or before December 23, 2025
Initiation of Allotment / Refunds / Unlocking of Funds from ASBA Account or UPI ID linked bank account	On or before December 24, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or before December 24, 2025
Commencement of trading of the Equity Shares on the Stock Exchange	On or before December 26, 2025

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY AS REGARDS ITS OBJECTS: For information on the main objects of our Company, please see the section "History and Certain Corporate Matters" on page 189 of the Prospectus. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, please see the section titled "Material Contracts and Documents for Inspection" on page 385 of the Prospectus.

LIABILITY OF THE MEMBERS AS PER MOA: LIMITED BY SHARES

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE

The Equity Share Capital of our Company, as on the date of the Prospectus is set forth below: (Amount in ₹ Lakhs)

Sr. No.	Particulars	Aggregate Value at Nominal Value	Aggregate Value at Issue Price
A	Authorized Share Capital		
	1,20,00,000 Equity Shares of ₹ 10/- each	1,200.00	-
B	Issued, Subscribed and Paid-Up Share Capital before the Issue		
	78,75,000 Equity Shares of ₹ 10/- each	787.50	-
C	Present Issue in terms of the Prospectus⁽¹⁾		
	Issue of 39,00,000 Equity Shares of face value of ₹ 10/- each at an Issue price of ₹ 98.00/- per Equity Share ⁽¹⁾	390.00	3,822.00
	Which comprises⁽²⁾:		
	1,96,800 Equity Shares of face value of ₹ 10/- each at a price of ₹ 98.00/- per Equity Share reserved as Market Maker Portion	19.68	192.86
	Net issue to Public of 37,03,200 Equity Shares of ₹ 10/- each at a price of ₹ 98.00/- per Equity Share to the Public	370.32	3,629.14
	Of Which:		
	Allocation of 18,51,600 Equity Shares aggregating ₹ 1,814.57 Lakhs will be available for allocation to Individual Investors who applies for minimum application size.	185.16	1,814.57
	Allocation of 18,51,600 Equity Shares aggregating ₹ 1,814.57 Lakhs will be available for allocation to other than Individual Investors who applies for minimum application size.	185.16	1,814.57
D	Issued, Subscribed and Paid-up Share Capital after the Issue		
	1,17,75,000 Equity Shares of face Value of ₹ 10/- each.	1,177.50	-
E	Securities Premium Account		
	Before the Issue		
	After the Issue		3,432.00

⁽¹⁾ The Issue has been authorized pursuant to a resolution of our Board dated May 30, 2025 and by Special Resolution passed under 62(1)(c) of the Companies Act, 2013 at the Extra-Ordinary General Meeting of our shareholders held on June 06, 2025.

⁽²⁾ Allocation to all categories shall be made on a proportionate basis subject to valid Applications received at or above the Issue Price. Under-subscription, if any, in any of the categories, would be allowed to be met with spill-over from any of the other categories or a combination of categories at the discretion of our Company in consultation with the Lead Manager and Stock Exchange. Such inter-se spill over, if any, would be affected in accordance with applicable laws, rules, regulations and guidelines.

For more details, see the chapter titled "Capital Structure" beginning on page 82 of the Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM

ORIGINAL SIGNATORIES			CURRENT PROMOTERS		
Name of Signatories	No. of Equity Shares Allotted	Face Value per share (in ₹)	Name of Promoters	No. of Equity Shares Allotted	Face Value per share (in ₹)
Hitarth Dave	6000	10.00/-	Niranjan Surana	29,00,000	10.00/-
Om Prakash Gupta	10	10.00/-	Shilpa Surana	2,50,000	10.00/-
Nirmal Prakash Nagar	3990	10.00/-	Aditi Bohra	12,73,175	10.00/-
			Bohra Agrifilms Private Limited	34,51,750	10.00/-

⁽¹⁾For more details, see the chapter titled "Capital Structure" beginning on page 82 of the Prospectus.

Listing: The Equity Shares to be Issued through the Prospectus are proposed to be listed on the SME Platform of BSE Limited ("BSE SME") in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time. Our Company has received an In-principal Approval letter dated September 11, 2025 from BSE Limited ("BSE") for using its name in Issue document for listing our shares on the BSE SME. For the purpose of this Issue, the Designated Stock Exchange will be BSE Limited ("BSE" or "the Stock Exchange").

Disclaimer Clause of SEBI: Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observations on the Offer document. Hence there is no such specific disclaimer clause of SEBI. However, Investors may refer to "Disclaimer Clause of SEBI" beginning on page 314 of the Prospectus.

Disclaimer Clause of BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the Prospectus has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the Prospectus. The investors are advised to refer to page 315 of the Prospectus for the full text of the Disclaimer Clause of BSE.

General Risk: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Prospectus. Specific attention of the investors is invited to "Risk Factors" beginning on page 29 of the Prospectus.

CORRIGENDUM: NOTICE TO INVESTORS

This corrigendum with respect to the prospectus dated December 12, 2025 ("Prospectus") filed with the RoC, SEBI and Stock Exchange in relation to the Offer. Potential investors should note the following:

- The table depicting "Basic and Diluted Earnings/Loss per Share" and "Price Earning (P/E) Ratio" in the chapter titled "Basis for Issue Price" beginning on page 109 of the Prospectus shall stand replaced with the below:

"1. Basic and Diluted Earnings/Loss per Share (EPS)", as adjusted for change in capital

As derived from the Restated Financial Statements:

Financial Year ended	Basic EPS (₹)	Diluted EPS (₹)	Weight
March 31, 2025	5.68	5.68	3
March 31, 2024	2.93	2.93	2
March 31, 2023	1.04	1.04	1
Weighted Average	4.00	4.00	-
Six months ended September 30, 2025*	4.77	4.77	-

* Not annualised

Notes:

- The face value of each Equity Share is ₹ 10.
- Basic Earnings per share = Restated Net profit after tax (loss after tax) as restated / Weighted average number of equity shares outstanding during the financial year, after considering impact of bonus retroactively for all period presented.
- Diluted Earnings per share = Restated Net profit after tax (loss after tax) as restated / Weighted average number of potential equity shares outstanding during the financial year, after considering impact of bonus retroactively for all period presented.
- Weighted Average = Aggregate of financial year-wise weighted EPS divided by the aggregate of weights i.e. (EPS x Weight) for each financial year / Total of weights.

2. Price Earning (P/E) Ratio in relation to the Issue Price of ₹ 98.00/- per Equity Share:

Particulars	P/E at the Issue Price (no. of times)
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	17.25
P/E ratio based on the Weighted Average EPS, as restated.	24.50




- Further, the entire Prospectus, the EPS and Diluted EPS without giving effect of Bonus and after giving effect of Bonus shall be as per considered as per below:

Sr. No.	Particulars	As at/ For the year ended/ period ended			
		September 30, 2025*	March 31, 2025	March 31, 2024	March 31, 2023
1.	Basic Earnings per Share as Restated	4.77	14.21	8.11	2.87
2.	Diluted Earnings per Share as Restated	4.77	14.21	8.11	2.87
3.	Basic Earnings per Share as Restated after considering Bonus Impact with retrospective effect	4.77	5.68	2.93	1.04
4.	Diluted Earnings per Share as Restated after considering Bonus Impact with retrospective effect	4.77	5.68	2.93	1.04

* Not Annualized

The information in this Corrigendum modifies and updates the information in the Prospectus and the Prospectus and the Bid cum Application Forms should be read in conjunction with this Corrigendum.

All capitalized term used in this Corrigendum shall, unless the context otherwise requires, have the same meaning ascribed to them in the Prospectus.

Lead Manager	Registrar to the Issue	Company Secretary and Compliance Office
 MEFCOM	 B	 PHYTOCHEM REMEDIES
Mefcom Capital Markets Limited G-II, Ground Floor, Dalamal House, Jammal Bajaj Marg, Nariman Point, Mumbai - 400021, Maharashtra, India. Tel: +91 (22) 3522 7026 E-mail: prli.ip@meffcomcap.in Website: www.mefcomcap.in Investor grievance: investor.grievance@mefcom.in SEBI Registration Number: INM00000016 Contact Person: Sushant Sonawane	Bigshare Services Private Limited S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, next to Ahura Centre, Andheri East, Mumbai- 400093, Maharashtra, India. Tel: +91 22 6263 8200 E-mail: ipo@bigshareonline.com Website: www.bigshareonline.com Investor Grievance ID: investor@bigshareonline.com SEBI Registration Number: INF000001385 Contact Person: Vinayak Morbale	Phytochem Remedies (India) Limited Namrata Paliwal, Compliance Officer Phytochem Remedies (India) Limited, 220, Ashok Nagar Main Road, Udaipur City, Udaipur, Girwa, Rajasthan- 313001, India E-mail: cs@phytochem.co.in Website: https://www.phytochem.co.in/ Corporate Identity Number: U17014RJ2002PLC017943

Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-issue or post-issue related grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-credit of funds by electronic mode, etc. For all issue related queries and for redressal of complaints, investors may also write to the Lead Manager.

AVAILABILITY OF PROSPECTUS: Investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus will be available at the website of SEBI at www.sebi.gov.in, the website of Stock Exchange at www.bseindia.com, the website of LM at www.mefcomcap.in and website of Company at www.phytochem.co.in/

AVAILABILITY OF ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, LM and BSE at www.phytochem.co.in/, www.mefcomcap.in and www.bseindia.com, respectively.

AVAILABILITY OF APPLICATION FORMS: Application forms can be obtained from the Company, Phytochem Remedies (India) Limited, Lead Manager: Mefcom Capital Markets Limited, Application Forms can also be obtained from the Stock Exchange and list of SCSEs available on the website of SEBI at www.sebi.gov.in and website of Stock Exchange at www.bseindia.com

APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA): All investors in this Issue have to compulsorily apply through ASBA. The investors are required to fill in the ASBA form and submit the same to their banks. The SCSEB will block the amount in the account as per the requirement in ASBA form. On allotment, amount will be unlocked, and the account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need for a refund.

For more details on the Issue process and how to apply, please refer to the details given in application forms and abridged prospectus and also please refer to the chapter "Issue Procedure" on page 334 of the Prospectus

BANKER TO THE ISSUE/ PUBLIC ISSUE ACCOUNT BANK/SPONSOR BANK: KOTAK MAHINDRA BANK LIMITED

UPI: Bidders can also bid through UPI mechanism

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus.

On behalf of Board of Directors
For Phytochem Remedies (India) Limited

Date: December 13, 2025

Place: Udaipur

Namrata Paliwal
Company Secretary and Compliance Officer

Phytochem Remedies (India) Limited, subject to market conditions and other considerations, Public Issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Jaipur on December 12, 2025. The Prospectus is available on the website of the Lead Manager at www.mefcomcap.in the website of the BSE i.e. www.bseindia.com, and website of our Company at www.phytochem.co.in/. Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Prospectus, including any corrigendum or supplement thereto and the section titled "Risk Factors" of the Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the U.S. Securities Act ("the Securities Act") or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulations under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.